JP2022512937A5 - - Google Patents
Info
- Publication number
- JP2022512937A5 JP2022512937A5 JP2021524317A JP2021524317A JP2022512937A5 JP 2022512937 A5 JP2022512937 A5 JP 2022512937A5 JP 2021524317 A JP2021524317 A JP 2021524317A JP 2021524317 A JP2021524317 A JP 2021524317A JP 2022512937 A5 JP2022512937 A5 JP 2022512937A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135834A JP2024161505A (ja) | 2018-11-08 | 2024-08-16 | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862757676P | 2018-11-08 | 2018-11-08 | |
| US62/757,676 | 2018-11-08 | ||
| US201962855988P | 2019-06-01 | 2019-06-01 | |
| US62/855,988 | 2019-06-01 | ||
| PCT/US2019/060622 WO2020097566A1 (en) | 2018-11-08 | 2019-11-08 | Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135834A Division JP2024161505A (ja) | 2018-11-08 | 2024-08-16 | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512937A JP2022512937A (ja) | 2022-02-07 |
| JPWO2020097566A5 JPWO2020097566A5 (https=) | 2022-11-07 |
| JP2022512937A5 true JP2022512937A5 (https=) | 2022-11-07 |
Family
ID=70612280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524317A Pending JP2022512937A (ja) | 2018-11-08 | 2019-11-08 | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
| JP2024135834A Pending JP2024161505A (ja) | 2018-11-08 | 2024-08-16 | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135834A Pending JP2024161505A (ja) | 2018-11-08 | 2024-08-16 | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210395358A1 (https=) |
| EP (1) | EP3877412A4 (https=) |
| JP (2) | JP2022512937A (https=) |
| KR (1) | KR20210089719A (https=) |
| CN (1) | CN112969711B (https=) |
| AU (1) | AU2019374905A1 (https=) |
| BR (1) | BR112021007633A2 (https=) |
| CA (1) | CA3117386A1 (https=) |
| WO (1) | WO2020097566A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20220073605A1 (en) * | 2018-12-20 | 2022-03-10 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| US20220288202A1 (en) * | 2019-09-04 | 2022-09-15 | Cedars-Sinai Medical Center | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients |
| KR20230009096A (ko) | 2021-07-08 | 2023-01-17 | 주식회사 엘지에너지솔루션 | 리튬 이차전지용 양극 슬러리 조성물, 양극 및 이를 포함하는 리튬 이차전지 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| HUE032563T2 (en) | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US20110111437A1 (en) * | 2009-10-08 | 2011-05-12 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomarkers For Prognosis of Pulmonary Diseases |
| WO2011066374A2 (en) * | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US20170174760A1 (en) * | 2015-07-24 | 2017-06-22 | Cedars-Sinai Medical Center | Method for treating antibody-mediated rejection post-transplantation |
| US20200123238A1 (en) * | 2017-04-19 | 2020-04-23 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
-
2019
- 2019-11-08 JP JP2021524317A patent/JP2022512937A/ja active Pending
- 2019-11-08 KR KR1020217017432A patent/KR20210089719A/ko active Pending
- 2019-11-08 WO PCT/US2019/060622 patent/WO2020097566A1/en not_active Ceased
- 2019-11-08 CN CN201980073394.4A patent/CN112969711B/zh active Active
- 2019-11-08 US US17/292,025 patent/US20210395358A1/en active Pending
- 2019-11-08 AU AU2019374905A patent/AU2019374905A1/en active Pending
- 2019-11-08 EP EP19881047.5A patent/EP3877412A4/en active Pending
- 2019-11-08 CA CA3117386A patent/CA3117386A1/en active Pending
- 2019-11-08 BR BR112021007633-6A patent/BR112021007633A2/pt unknown
-
2024
- 2024-08-16 JP JP2024135834A patent/JP2024161505A/ja active Pending